Agilent Technologies, Inc. (NYSE:A) SVP Dominique Grau Sells 9,990 Shares

Agilent Technologies, Inc. (NYSE:A) SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Agilent Technologies Stock Up 0.9 %

A stock opened at $148.06 on Monday. The company has a 50 day moving average price of $138.91 and a two-hundred day moving average price of $138.99. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The stock has a market capitalization of $43.20 billion, a P/E ratio of 35.00, a PEG ratio of 6.48 and a beta of 1.05. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm posted $1.43 earnings per share. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st will be paid a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is currently 22.22%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group lifted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. TD Cowen upped their target price on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Wells Fargo & Company initiated coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective on the stock. Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Finally, Evercore ISI increased their price target on shares of Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $142.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Western Pacific Wealth Management LP raised its holdings in Agilent Technologies by 18.9% in the first quarter. Western Pacific Wealth Management LP now owns 440 shares of the medical research company’s stock valued at $64,000 after buying an additional 70 shares during the period. Ballentine Partners LLC lifted its holdings in Agilent Technologies by 2.5% in the 1st quarter. Ballentine Partners LLC now owns 2,963 shares of the medical research company’s stock worth $431,000 after buying an additional 73 shares in the last quarter. Haverford Trust Co boosted its holdings in Agilent Technologies by 1.7% in the first quarter. Haverford Trust Co now owns 4,423 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 74 shares during the last quarter. Menard Financial Group LLC grew its position in shares of Agilent Technologies by 1.6% during the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after buying an additional 77 shares in the last quarter. Finally, Salem Investment Counselors Inc. grew its holdings in Agilent Technologies by 4.4% during the 1st quarter. Salem Investment Counselors Inc. now owns 2,259 shares of the medical research company’s stock worth $329,000 after acquiring an additional 95 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.